Quest Diagnostics Inc (New York Stock Exchange:DGX)
| Market Cap | 25.99B+30.7% |
| Revenue (ttm) | 11.56B+9.9% |
| Net Income | 1.06B+11.8% |
| EPS | 9.42+12.8% |
| Shares Out | 110.37M |
| PE Ratio | 24.68 |
| Forward PE | 19.53 |
| Dividend | $3.32(1.41%) |
| Ex-Dividend Date | Oct 6, 2026 |
| Volume | 782,154 |
| Open | 234.91 |
| Previous Close | 235.50 |
| Day's Range | 232.43 - 236.25 |
| 52-Week Range | 171.18 - 247.19 |
| Beta | 0.55 |
| Analysts | Hold |
| Price Target | 246.67(+4.76%) |
| Earnings Date | Oct 20, 2026 |
About DGX
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$DGX stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of DGX by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Carol Devine MillerHouse / R | Sale$15.00K – $50.00K | Mar 10, 2025 |
| Carol Devine MillerHouse / R | Sale$15.00K – $50.00K | Mar 9, 2025 |
| Carol Devine MillerHouse / R | Sale$1.00K – $15.00K | Mar 9, 2025 |
| Carol Devine MillerHouse / R | Purchase$1.00K – $15.00K | Nov 13, 2022 |
| Carol Devine MillerHouse / R | Purchase$15.00K – $50.00K | Jul 27, 2021 |
Recently reported changes in DGX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DGX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DGX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New DGX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DGX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in DGX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $821.35M |
| VOOVanguard S&P 500 ETF | $677.02M |
| VOVanguard Morningstar Mid-Cap ETF | $558.22M |
| IVViShares Core S&P 500 ETF | $345.78M |
| SPYState Street SPDR S&P 500 ETF | $320.35M |
| VTVVanguard Morningstar Value ETF | $245.76M |
Estimated from each fund’s disclosed top holdings × AUM
DGX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from DGX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score